graft-versus-host disease

(redirected from Graft-vs-host disease)
Also found in: Medical.

graft-ver·sus-host disease

(grăft′vûr′səs-hōst′, -səz-)
n.
A condition in which cells from the transplanted tissue of a donor initiate an immunologic attack on the cells and tissue of the recipient.

graft′-ver`sus-host′ disease`


n.
a reaction in which the cells of transplanted tissue immunologically attack the cells of the host.
Mentioned in ?
References in periodicals archive ?
Grafalon is indicated in solid organ transplant for prevention and treatment of acute rejection, graft-vs-host disease (GvHD) in stem cell transplant (SCT) and in the treatment of aplastic anemia.
Grafalon is a rabbit anti-human T-lymphocyte immunoglobulin used, where approved, as part of immunosuppressive regimens for the prevention of graft-vs-host disease in stem cell transplant, prevention and treatment of rejection in solid organ transplantation, or as immunosuppressive in the treatment of aplastic anemia.
Toxic epidermal necrolysis from graft-vs-host disease: occurrence in a patient with thymic hypoplasia.
Conjunctival graft-vs-host disease," Archives of Ophthalmology, vol.
Arora, "Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease," Translational Research, vol.
Pathogen-reduced platelets also benefit our sickest patients by eliminating the rare but deadly graft-vs-host disease.
Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
Prochymal (remestemcel-L) is a first-in-class mesenchymal stem cell therapy indicated for the treatment of acute graft-vs-host disease (GvHD) in children.
According to Osiris Therapeutics Inc, Prochymal (remestemcel-L) is a first-in-class mesenchymal stem cell therapy indicated for the treatment of acute graft-vs-host disease (GvHD) in children.
Osiris Therapeutics, Inc., Columbia, MD, announced it has received market authorization from both Health Canada and the country of New Zealand to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease (GvHD) in children.